CSLLY vs EW
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CSLLY · CSL LTD SPON ADR EACH REPR 0.25 ORD$34.76 ▼ 0.57%
EW · Edwards Lifesciences$102.14 ▲ 1.31%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CSLLY +22.1%
- EW +21.5%
Head to head
| Metric | CSLLY | EW |
|---|---|---|
| Price | $34.76 | $102.14 |
| Change today | ▼ 0.57% | ▲ 1.31% |
| Market cap | $58.62B | $58.73B |
| Return, 3 months | +48.2% | +11.0% |
| Return, year to date | +23.8% | +19.8% |
| Return, 1 year | +22.8% | +22.5% |
| P/E (TTM) | – | 57.7 |
| P/B | 4.5 | 5.4 |
| P/E percentile vs own 5y | – | 100th |
| Dividend yield | 2.04% | – |
| Revenue growth (YoY, latest qtr) | – | +13.6% |
| Net profit growth (YoY) | – | -27.2% |
| Gross margin | – | 77.8% |
| Operating margin | – | 28.1% |
| Net margin | – | 15.4% |
| Return on equity | – | 9.5% |
| Analyst target vs. price | – | +12.8% |
| Analyst buy share | – | 95% |
| RSI (14) | 63 | 77 |
| 30-day volatility | 20.6% | 25.8% |
| Max drawdown, 1 year | -52.2% | -13.2% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- EW is the largest of the group by market value.
- CSLLY has returned the most over the past year.
- CSLLY has been the calmest stock over the last 30 days.